What is eloralintide, and how is it different from cagrilintide or a GLP-1 drug?
An emerging amylin approach with human trial evidence.
Eloralintide is an investigational selective amylin-receptor agonist. Amylin is involved in meal-related satiety signaling, so this approach differs from directly activating GLP-1 receptors. Cagrilintide is also an amylin-based drug, but the two molecules are not interchangeable. CagriSema specifically combines cagrilintide with the GLP-1 drug semaglutide.[1][2]
A 48-week randomized phase 2 trial in 263 adults without type 2 diabetes found substantial weight reductions with eloralintide compared with placebo. Nausea and fatigue were among the commonly reported adverse events. This supplies human evidence beyond the mechanism, while leaving longer-term outcomes and the best use of the drug to further study.[1]
Comparing its headline percentage with a separate cagrilintide or GLP-1 trial does not establish which treatment is better. Trial populations, duration, adherence, and statistical handling of treatment discontinuation differ. The meaningful next questions concern direct comparisons, tolerability, durability, and body composition, not simply which emerging name has the largest number attached to it.[1][2]
Sources & further reading
- Eloralintide: 48-week randomized phase 2 obesity trial
- REDEFINE 1: cagrilintide and semaglutide in adults with obesity
Updated September 24, 2026 · Evidence summaries for understanding research.
Q&A episodes behind this question
This question draws on the following public Q&A topics. The answer above is independently researched and does not quote or represent either creator’s advice.
- Vigorous Steve: BAM15 Vs. ATX-304, Cagrilintide Vs. Eloralintide, SLU-PP-915, Mirabegron, Omegatide Vs. MetatrutidePublished episode title and description